# Clinical trials to prevent Alzheimer's Disease in Down Syndrome

> **NIH NIH R61** · UNIVERSITY OF SOUTHERN CALIFORNIA · 2020 · $998,408

## Abstract

TITLE: NIH INCLUDE ACTC-DS – Bringing Advances in Tau PET imaging and blood-
based biomarkers of Phospho-tau to the Trial-Ready Cohort – Down Syndrome (TRC-DS)
ABSTRACT
With this supplement, we request funding to implement multiple new assays to be performed on
CSF and blood samples as well as the addition of Tau PET imaging on half of the participants in
the Alzheimer's Clinical Trial Consortium – Down Syndrome (ACTC-DS) Trial Ready Cohort –
Down syndrome (TRC-DS) Project. Tau PET is a critical biomarker in understanding AD
pathology in DS and as in the sporadic population, seems to correlate more closely with
cognitive decline. Moreover, recent findings indicate that Pospho-Tau-217 (Ptau217) may
represent perhaps the most accurate CSF- and blood-based biomarker of AD and will thus be
critically important to study in the DS population.

## Key facts

- **NIH application ID:** 10249007
- **Project number:** 3R61AG066543-02S1
- **Recipient organization:** UNIVERSITY OF SOUTHERN CALIFORNIA
- **Principal Investigator:** Michael S Rafii
- **Activity code:** R61 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $998,408
- **Award type:** 3
- **Project period:** 2019-09-15 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10249007

## Citation

> US National Institutes of Health, RePORTER application 10249007, Clinical trials to prevent Alzheimer's Disease in Down Syndrome (3R61AG066543-02S1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10249007. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*